Search Results
Baxter to Present at the 2019 Wells Fargo Healthcare Conference
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 2019 Wells Fargo Healthcare Conference in Boston on September 5, 2019. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 1:20 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through March 3, 2020. About Baxter
Baxter Recognized with Highest Achievement on 2019 Diversity Best Practices Inclusion Index
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced it has been named a 2019 Top 10 Percent Inclusion Index Company, the highest-scoring category of Diversity Best Practices’ (DBP) annual Inclusion Index. Of the 148 companies that participated this year, Baxter is one of just 14 recognized for superior achievement in creating an inclusive workplace.
Baxter Supports Add-On Payment in Proposed ESRD Payment Rule to Spur Innovation for Dialysis Patients
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today issued this statement:
Baxter Launches PrisMax in U.S. to Maximize Care for Critically Ill Patients
Baxter International Inc.
Baxter Adds Finomel With Fish Oil to Ready-To-Use Parenteral Nutrition Portfolio
Baxter International Inc. (NYSE:BAX), a global leader in clinical nutrition, announced today the European launch of Finomel, a ready-to-use triple-chamber bag for parenteral nutrition (PN). Finomel expands the company’s portfolio of leading premixed PN formulations and offers healthcare providers with additional options to meet adult patients’ diverse nutritional needs.
Baxter Reports Second-Quarter 2019 Results
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported earnings for the second quarter of 2019 and updated its full-year 2019 earnings outlook.
Baxter Announces U.S. FDA Approval of Myxredlin, the First and Only Ready-To-Use Insulin for IV Infusion
Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration (FDA) approval of Myxredlin (Insulin Human in 0.9% Sodium Chloride Injection).
Baxter Declares Quarterly Dividend
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.22 per share of common stock. The dividend is payable on October 1, 2019, to shareholders of record as of August 30, 2019. The indicated annual dividend rate is $0.88 per share of common stock. About Baxter
Baxter Supports Advancing American Kidney Health Initiative and Plans Significant U.S. Investment to Help Drive Implementation
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced its full support of the Administration’s Advancing American Kidney Health Initiative introduced today. The company plans to make the necessary investments to support implementation, which are expected to result in new U.S. manufacturing capacity and the creation of high-quality U.S. jobs.
Baxter Highlights Progress Toward Its 2020 Corporate Responsibility Goals and Efforts to Make a Meaningful Difference Around the World
Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced today the release of its 2018 Corporate Responsibility Report, which showcases the company’s progress on key initiatives to drive more sustainable operations, enhance product quality, build healthy communities, foster a strong work environment and improve access to healthcare.